OneSource Specialty Pharma shares plunged 18% after reporting a net loss of Rs 47 crore for the December quarter, a significant reversal from the previous year’s profit. Revenue dropped 26% year-on-year, impacted by delayed semaglutide approvals in Canada. Despite the weak quarter, the company reaffirmed its FY28 revenue guidance.